Amedeo Lucente, Andrea Taloni, Federico Fava, Giuseppe Giannaccare
{"title":"局部吲哚美辛治疗预防视网膜前膜牵拉进展：1例报告及文献复习。","authors":"Amedeo Lucente, Andrea Taloni, Federico Fava, Giuseppe Giannaccare","doi":"10.7573/dic.2025-2-4","DOIUrl":null,"url":null,"abstract":"<p><p>This case report explores the potential of 0.5% indomethacin eye drops (Indo0.5) in preventing the progression of epiretinal membrane traction. A 72-year-old patient with progressive vitreomacular traction was treated with Indo0.5, leading to a significant decrease in intraretinal cyst within 8 months, complete resorption after 16 months and full restoration of the retinal profile after 22 months. A mini literature review highlights the anti-inflammatory effects of indomethacin for various conditions affecting the anterior segment and suggests that the 0.5% concentration may also be effective in managing retinal inflammation. Indo0.5 could be a non-invasive option for slowing epiretinal membrane traction progression, supporting further research to optimize treatment strategies.</p>","PeriodicalId":11362,"journal":{"name":"Drugs in Context","volume":"14 ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12221134/pdf/","citationCount":"0","resultStr":"{\"title\":\"Prevention of epiretinal membrane traction progression with topical indomethacin treatment: a case report and mini literature review.\",\"authors\":\"Amedeo Lucente, Andrea Taloni, Federico Fava, Giuseppe Giannaccare\",\"doi\":\"10.7573/dic.2025-2-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>This case report explores the potential of 0.5% indomethacin eye drops (Indo0.5) in preventing the progression of epiretinal membrane traction. A 72-year-old patient with progressive vitreomacular traction was treated with Indo0.5, leading to a significant decrease in intraretinal cyst within 8 months, complete resorption after 16 months and full restoration of the retinal profile after 22 months. A mini literature review highlights the anti-inflammatory effects of indomethacin for various conditions affecting the anterior segment and suggests that the 0.5% concentration may also be effective in managing retinal inflammation. Indo0.5 could be a non-invasive option for slowing epiretinal membrane traction progression, supporting further research to optimize treatment strategies.</p>\",\"PeriodicalId\":11362,\"journal\":{\"name\":\"Drugs in Context\",\"volume\":\"14 \",\"pages\":\"\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-06-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12221134/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drugs in Context\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.7573/dic.2025-2-4\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drugs in Context","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7573/dic.2025-2-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
Prevention of epiretinal membrane traction progression with topical indomethacin treatment: a case report and mini literature review.
This case report explores the potential of 0.5% indomethacin eye drops (Indo0.5) in preventing the progression of epiretinal membrane traction. A 72-year-old patient with progressive vitreomacular traction was treated with Indo0.5, leading to a significant decrease in intraretinal cyst within 8 months, complete resorption after 16 months and full restoration of the retinal profile after 22 months. A mini literature review highlights the anti-inflammatory effects of indomethacin for various conditions affecting the anterior segment and suggests that the 0.5% concentration may also be effective in managing retinal inflammation. Indo0.5 could be a non-invasive option for slowing epiretinal membrane traction progression, supporting further research to optimize treatment strategies.
期刊介绍：
Covers all phases of original research: laboratory, animal and human/clinical studies, health economics and outcomes research, and postmarketing studies. Original research that shows positive or negative results are welcomed. Invited review articles may cover single-drug reviews, drug class reviews, latest advances in drug therapy, therapeutic-area reviews, place-in-therapy reviews, new pathways and classes of drugs. In addition, systematic reviews and meta-analyses are welcomed and may be published as original research if performed per accepted guidelines. Editorials of key topics and issues in drugs and therapeutics are welcomed. The Editor-in-Chief will also consider manuscripts of interest in areas such as technologies that support diagnosis, assessment and treatment. EQUATOR Network reporting guidelines should be followed for each article type. GPP3 Guidelines should be followed for any industry-sponsored manuscripts. Other Editorial sections may include Editorial, Case Report, Conference Report, Letter-to-the-Editor, Educational Section.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
